You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GD2

Showing 1 - 25 of 3,714
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma Trial (GD2 CAR T cells)

Not yet recruiting
  • Neuroblastoma
  • GD2 CAR T cells
  • (no location specified)
Aug 5, 2023

Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)

Completed
  • Sarcoma
  • +3 more
  • Anti-GD2-CAR engineered T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma Trial in Bethesda, Seattle, Madison (Cyclophosphamide,

Recruiting
  • Recurrent Neuroblastoma
  • +3 more
  • Palo Alto, California
  • +3 more
Jan 25, 2023

Neuroblastoma Trial in Houston (iC9-GD2 T Cells - frozen, iC9-GD2 T Cells - fresh, Cytoxan)

Active, not recruiting
  • Neuroblastoma
  • iC9-GD2 T Cells - frozen
  • +5 more
  • Houston, Texas
  • +1 more
Jan 4, 2023

Solid Tumor Trial in Shenzhen (bi-4SCAR GD2/PSMA T cells)

Recruiting
  • Solid Tumor
  • bi-4SCAR GD2/PSMA T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Diffuse Midline Glioma, H3 K27M-Mutant Trial (GD2 CAR T cells)

Not yet recruiting
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • GD2 CAR T cells
  • (no location specified)
Sep 15, 2022

Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T Infusion)

Not yet recruiting
  • Lung Cancer
  • +2 more
  • iC9.GD2.CAR.IL-15 T Infusion
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Nov 16, 2022

Cancer Disease Trial in Shenzhen (bi-4SCAR GD2/CD70 T cells)

Recruiting
  • Cancer Disease
  • bi-4SCAR GD2/CD70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Malignant Disease Trial in Shenzhen (bi-4SCAR GD2/CD56 T cells)

Recruiting
  • Malignant Disease
  • bi-4SCAR GD2/CD56 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in Columbus (procedure, drug, biological)

Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • HER2-Negative Breast Carcinoma
  • Biospecimen Collection
  • +5 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 30, 2023

SCLC, Malignant Melanoma, Sarcoma Trial (GD2-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • SCLC
  • +2 more
  • GD2-SADA:177Lu-DOTA Complex
  • (no location specified)
May 4, 2022

Neuroblastoma, Neuroblastoma Recurrent, GD2-positive Solid Tumors Trial in Roma (GD2-CART01)

Recruiting
  • Neuroblastoma
  • +5 more
  • GD2-CART01
  • Roma, Italy
    Ospedale Pediatrico Bambino Gesù
Mar 9, 2022

Neuroblastoma Trial in Houston (GINAKIT Cells, Cyclophosphamide, Fludarabine)

Active, not recruiting
  • Neuroblastoma
  • GINAKIT Cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Jan 18, 2023

Glioma of Spinal Cord, Glioma of Brainstem Trial in Stanford (GD2 CAR T cells, Fludarabine, Cyclophosphamide)

Recruiting
  • Glioma of Spinal Cord
  • Glioma of Brainstem
  • GD2 CAR T cells
  • +2 more
  • Stanford, California
    Lucile Packard Children's Hospital (LPCH)
Jun 22, 2022

Neuroblastoma, Osteosarcoma Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine)

Recruiting
  • Neuroblastoma
  • Osteosarcoma
  • iC9.GD2.CAR.IL-15 T-cells
  • +2 more
  • Atlanta, Georgia
  • +1 more
Jan 4, 2023

Brain Tumor, Pediatric, Medulloblastoma, Childhood, Embryonal Tumor Trial (GD2-CART01 (iC9-GD2-CAR T-cells))

Not yet recruiting
  • Brain Tumor, Pediatric
  • +6 more
  • GD2-CART01 (iC9-GD2-CAR T-cells)
  • (no location specified)
Mar 18, 2022

Diffuse Intrinsic Pontine Glioma, High Grade Glioma, Embryonal Tumor Trial in Houston ((C7R)-GD2.CART cells, Cyclophosphamide,

Recruiting
  • Diffuse Intrinsic Pontine Glioma
  • +3 more
  • (C7R)-GD2.CART cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Feb 7, 2022

Neuroblastoma, Ganglioneuroblastoma Trial in Moscow (monoclonal antibodies GD2)

Recruiting
  • Neuroblastoma
  • Ganglioneuroblastoma
  • monoclonal antibodies GD2
  • Moscow, Russian Federation
    Research Institute of Pediatric Hematology, Oncology and Immunol
Oct 4, 2023

Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma Trial in Houston (C7R-GD2.CART cells, Cyclophosphamide,

Recruiting
  • Relapsed Neuroblastoma
  • +6 more
  • C7R-GD2.CART cells
  • +2 more
  • Houston, Texas
  • +1 more
Nov 12, 2021

Neuroblastoma, Effects of Immunotherapy Trial in Guangzhou (Anti-GD2 CART)

Suspended
  • Neuroblastoma
  • Effects of Immunotherapy
  • Anti-GD2 CART
  • Guangzhou, Guangdong, China
    Zhujiang Hospital of Southern Medical University
Aug 2, 2021

Neuroblastoma, High-Risk Trial in New York (cyclophosphamide, NK cells, hu3F8)

Active, not recruiting
  • Neuroblastoma
  • High-Risk
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 14, 2022

Neuroblastoma Trial in Houston (EBV specific CTLs)

Active, not recruiting
  • Neuroblastoma
  • EBV specific CTLs
  • Houston, Texas
    Texas Children's Hospital
Feb 2, 2022

Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma Trial in Atlanta (Ex Vivo Expanded Allogeneic ?d T Cells in

Not yet recruiting
  • Neuroblastoma
  • +2 more
  • Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
  • Atlanta, Georgia
    Children's Healthcare of Atlanta
Oct 6, 2022

Osteosarcoma, Neuroblastoma Trial in Houston (genetic, biological, drug)

Active, not recruiting
  • Osteosarcoma
  • Neuroblastoma
  • GD2 T cells
  • +3 more
  • Houston, Texas
  • +1 more
Apr 16, 2021

SCLC Trial in United States (Nivatrotamab)

Terminated
  • SCLC
  • Tampa, Florida
  • +6 more
Jul 11, 2022